Compare GLDD & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GLDD | NUVB |
|---|---|---|
| Founded | 1890 | 2018 |
| Country | United States | United States |
| Employees | N/A | 298 |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.7B |
| IPO Year | 2007 | N/A |
| Metric | GLDD | NUVB |
|---|---|---|
| Price | $17.00 | $4.72 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | ★ $17.00 | $11.38 |
| AVG Volume (30 Days) | 2.5M | ★ 4.2M |
| Earning Date | 05-05-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 28.57 | N/A |
| EPS | ★ 1.08 | N/A |
| Revenue | ★ $702,503,000.00 | N/A |
| Revenue This Year | $5.19 | $203.82 |
| Revenue Next Year | $7.56 | $58.18 |
| P/E Ratio | $15.74 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $10.37 | $1.57 |
| 52 Week High | $17.02 | $9.75 |
| Indicator | GLDD | NUVB |
|---|---|---|
| Relative Strength Index (RSI) | 68.41 | 48.38 |
| Support Level | $14.60 | $4.07 |
| Resistance Level | N/A | $5.16 |
| Average True Range (ATR) | 0.03 | 0.28 |
| MACD | -0.06 | 0.02 |
| Stochastic Oscillator | 80.00 | 60.94 |
Great Lakes Dredge & Dock Corp is a provider of dredging services in the United States. The Company is also fully engaged in expanding its core business into the offshore energy industry. Dredging involves the enhancement or preservation of the navigability of waterways or the protection of shorelines through the removal or replenishment of soil, sand, or rock. Company work generally is to performed in coastal waterways and deep water ports. Its project portfolio includes Coastal Restoration, Coastal Protection, Ports and Harbors, International, and Inland Dredging.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.